In Q3 2020 – months after completing its spinout from Philips – Neolook signed its first independent institutional deal with Máxima Medisch Centrum (MMC), one of the Netherlands' leading academic NICUs. The engagement was executed under active COVID-19 pandemic conditions and structured from the outset as a scalable partnership, not a one-off pilot.
The deal was anchored by a named clinical champion: Dr. Thilo Mohns, neonatoloog, afdelingshoofd, and CMIO at MMC. At a clinical presentation of S2S Family, Dr. Mohns stated unprompted: "you are doing something we have been waiting for for a very long time." MMC committed to scaling the solution contingent on successful initial deployment.
Three factors make this an unusually strong proof point. First, clinical pull, not commercial push: the engagement was initiated by the CMIO and department head of neonatology based on independent clinical conviction. Second, COVID-19 deployment: hospitals in Q3 2020 had every structural incentive to defer new technology partnerships – MMC moved forward, which directly signals the urgency of the unmet need. Third, scale-up commitment from day one: MMC did not treat this as an experiment and committed from the outset to expanding the deployment if the initial phase proved successful.
This proof point anchors the S2S Family lineage in the Neolook venture narrative. It is the first post-Philips, externally validated confirmation that S2S Family addresses a named, urgent clinical need – and that Neolook can win institutional deals on clinical conviction alone.
Source: Fibery PP-213 · Máxima Medisch Centrum · Q3 2020